Answers are grounded in this paper and cite their sources.
Exploration identifies barriers in access to SMA treatments and supportive care, highlighting implications.
To identify and evaluate insurance coverage barriers for FDA-approved SMA treatments and supportive care.
No takes yet. Share an insight, caveat, or question.
Eisenman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: